SecBot SecBot
SECBOTREPLAY Home › Report › RPRX

RPRX · Royalty Pharma reported Q2 2026 results with Portfolio Receipts of…

Royalty Pharma plc · 8-K filed Aug 5, 2026 at 07:33 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 5, 2026 at 07:33 ET

Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cash Flow per diluted share of $1.32, beating the $1.27 consensus by 3.9%. The company raised its full-year 2026 Portfolio Receipts guidance to $3,400-$3,500 million from $3,325-$3,450 million, driven by strong 14% Royalty Receipts growth from Tremfya, Voranigo, Imdelltra, and Evrysdi.

  • Portfolio Receipts of $773M in Q2 2026, up 6% YoY from $727M
  • Royalty Receipts of $768M, up 14% YoY from $672M
  • Portfolio Cash Flow of $736M, up 15% YoY from $641M
  • EPS (Portfolio Cash Flow per share) of $1.32 vs consensus $1.27 (beat by 3.9%)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access